Literature DB >> 16230340

Novel fluorescent prothrombin analogs as probes of staphylocoagulase-prothrombin interactions.

Peter Panizzi1, Rainer Friedrich, Pablo Fuentes-Prior, Heather K Kroh, Judy Briggs, Guido Tans, Wolfram Bode, Paul E Bock.   

Abstract

Staphylocoagulase (SC) is a potent nonproteolytic prothrombin (ProT) activator and the prototype of a newly established zymogen activator and adhesion protein family. The staphylocoagulase fragment containing residues 1-325 (SC-(1-325)) represents a new type of nonproteolytic activator with a unique fold consisting of two three-helix bundle domains. The N-terminal, domain 1 of SC (D1, residues 1-146) interacts with the 148 loop of thrombin and prethrombin 2 and the south rim of the catalytic site, whereas domain 2 of SC (D2, residues 147-325) occupies (pro)exosite I, the fibrinogen (Fbg) recognition exosite. Reversible conformational activation of ProT by SC-(1-325) was used to create novel analogs of ProT covalently labeled at the catalytic site with fluorescence probes. Analogs selected from screening 10 such derivatives were used to characterize quantitatively equilibrium binding of SC-(1-325) to ProT, competitive binding with native ProT, and SC domain interactions. The results support the conclusion that SC-(1-325) binds to a single site on fluorescein-labeled and native ProT with indistinguishable dissociation constants of 17-72 pM. The results obtained for isolated SC domains indicate that D2 binds ProT with approximately 130-fold greater affinity than D1, yet D1 binding accounts for the majority of the fluorescence enhancement that accompanies SC-(1-325) binding. The SC-(1-325).(pro)thrombin complexes and free thrombin showed little difference in substrate specificity for tripeptide substrates or with their natural substrate, Fbg. Lack of a significant effect of blockage of (pro)exosite I of (pro)thrombin by SC-(1-325) on Fbg cleavage indicates that a new Fbg substrate recognition exosite is expressed on the SC-(1-325).(pro)thrombin complexes. Our results provide new insight into the mechanism that mediates zymogen activation by this prototypical bacterial activator.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230340      PMCID: PMC2292460          DOI: 10.1074/jbc.M507955200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  An extensive interaction interface between thrombin and factor V is required for factor V activation.

Authors:  T Myles; T H Yun; S W Hall; L L Leung
Journal:  J Biol Chem       Date:  2001-04-18       Impact factor: 5.157

2.  Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation.

Authors:  Rainer Friedrich; Peter Panizzi; Pablo Fuentes-Prior; Klaus Richter; Ingrid Verhamme; Patricia J Anderson; Shun-Ichiro Kawabata; Robert Huber; Wolfram Bode; Paul E Bock
Journal:  Nature       Date:  2003-10-02       Impact factor: 49.962

3.  Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.

Authors:  X Wang; X Lin; J A Loy; J Tang; X C Zhang
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

4.  Polyethylene glycol 6,000 enhancement of the clotting of fibrinogen solutions in visual and mechanical assays.

Authors:  J W Fenton; M J Fasco
Journal:  Thromb Res       Date:  1974-06       Impact factor: 3.944

5.  Difference in enzymatic properties between alpha-thrombin-staphylocoagulase complex and free alpha-thrombin.

Authors:  S Kawabata; T Morita; S Iwanaga; H Igarashi
Journal:  J Biochem       Date:  1985-04       Impact factor: 3.387

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

7.  Papain labelled with fluorescent thiol-specific reagents as a probe for characterization of interactions between cysteine proteinases and their protein inhibitors by competitive titrations.

Authors:  P Lindahl; E Raub-Segall; S T Olson; I Björk
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

8.  The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans.

Authors:  V M Van Deerlin; D M Tollefsen
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

9.  The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships.

Authors:  W Bode; D Turk; A Karshikov
Journal:  Protein Sci       Date:  1992-04       Impact factor: 6.725

10.  The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors:  T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal:  Science       Date:  1990-07-20       Impact factor: 47.728

View more
  23 in total

Review 1.  Exploring Staphylococcus aureus pathways to disease for vaccine development.

Authors:  Andrea DeDent; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Semin Immunopathol       Date:  2011-12-01       Impact factor: 9.623

2.  Effect of zymogen domains and active site occupation on activation of prothrombin by von Willebrand factor-binding protein.

Authors:  Heather K Kroh; Paul E Bock
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

3.  Restricted active site docking by enzyme-bound substrate enforces the ordered cleavage of prothrombin by prothrombinase.

Authors:  Ayse Hacisalihoglu; Peter Panizzi; Paul E Bock; Rodney M Camire; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

4.  Inhibition of thrombin formation by active site mutated (S360A) activated protein C.

Authors:  Gerry A F Nicolaes; Paul E Bock; Kenneth Segers; Karin C A A Wildhagen; Björn Dahlbäck; Jan Rosing
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

5.  Engineering streptokinase for generation of active site-labeled plasminogen analogs.

Authors:  Malabika Laha; Peter Panizzi; Matthias Nahrendorf; Paul E Bock
Journal:  Anal Biochem       Date:  2011-04-23       Impact factor: 3.365

6.  Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes.

Authors:  Jennifer L Newell-Caito; Malabika Laha; Anthony C Tharp; Jonathan I Creamer; Hong Xu; Ashoka A Maddur; Guido Tans; Paul E Bock
Journal:  J Biol Chem       Date:  2011-09-12       Impact factor: 5.157

Review 7.  Endocarditis and molecular imaging.

Authors:  Peter Panizzi; James R Stone; Matthias Nahrendorf
Journal:  J Nucl Cardiol       Date:  2014-05-06       Impact factor: 5.952

8.  Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear.

Authors:  Michelle A Berny; Imke C A Munnix; Jocelyn M Auger; Saskia E M Schols; Judith M E M Cosemans; Peter Panizzi; Paul E Bock; Steve P Watson; Owen J T McCarty; Johan W M Heemskerk
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

9.  A novel mode of intervention with serine protease activity: targeting zymogen activation.

Authors:  Grant E Blouse; Kenneth A Bøtkjaer; Elena Deryugina; Aleksandra A Byszuk; Janni M Jensen; Kim K Mortensen; James P Quigley; Peter A Andreasen
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

10.  Specificity and affinity of the N-terminal residues in staphylocoagulase in binding to prothrombin.

Authors:  Ashoka A Maddur; Heather K Kroh; Mary E Aschenbrenner; Breanne H Y Gibson; Peter Panizzi; Jonathan H Sheehan; Jens Meiler; Paul E Bock; Ingrid M Verhamme
Journal:  J Biol Chem       Date:  2020-03-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.